Asia Pacific Filgrastim Market By Drug Type, By Indication, By Distribution Channel, By Country, Opportunity Analysis and Industry Forecast, 2021 - 2027

The Asia Pacific Filgrastim Market is expected to witness market growth of 9.4% CAGR during the forecast period (2021-2027).

Factor like the rising population of cancer patients, especially in developing nations like China and India, is expected to unlock bright prospects for the Filgrastim market in the coming years. Although, the high cost attached to these biologics and strict regulatory compliance for the approval of biosimilars in developed nations is expected to hamper the growth of the filgrastim market in the forecast years.

There are several biosimilars research going on across the world, which is expected to accelerate the growth of the market. In addition, the availability of strong pipeline drugs is also estimated to support the growth of the filgrastim market over the forecast period.

One of the major factors augmenting the demand for filgrastim in this region is the increasing cases of cancer in developing nations like India and China. Governments across this region are taking many initiatives to aware people of the early treatment, which is estimated to propel the growth of the regional filgrastim market in the forecast period. However, many people with a low-income level cannot afford treatment for various chronic diseases, especially cancer. This is expected to restrict the demand for filgrastim in the regional market.

Furthermore, as the healthcare system of this region is becoming stronger and governments are introducing better and cheaper healthcare facilities for the people, the demand for filgrastim is expected to increase across this region. Although, the side effects of using filgrastim and the availability of various better alternatives is expected to hinder the growth of the regional filgrastim market during the forecast period.

The China market dominated the Asia Pacific Filgrastim Market by Country in 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $60.3 million by 2027. The Japan market is experiencing a CAGR of 10.4% during (2021 - 2027). Additionally, The India market is expected to witness a CAGR of 10.4% during (2021 - 2027).

Based on Drug Type, the market is segmented into Biosimilar and Biologic. Based on Indication, the market is segmented into Chemotherapy induced Neutropenia, Chronic Neutropenia and Other Indications. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Amgen, Inc., Pfizer, Inc., Novartis AG, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Kyowa Kirin Co., Ltd. (Kirin Company), Cadila Healthcare Ltd. (Zydus Cadila), Apotex, Inc., and Toksöz Group

Scope of the Study

Market Segments Covered in the Report:

By Drug Type

• Biosimilar and
• Biologic

By Indication

• Chemotherapy induced Neutropenia
• Chronic Neutropenia and
• Other Indications

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies and
• Online Pharmacies

By Country

• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific

Key Market Players

List of Companies Profiled in the Report:

• Abbott Laboratories
• Amgen, Inc.
• Pfizer, Inc.
• Novartis AG
• Dr. Reddy’s Laboratories Ltd.
• Teva Pharmaceutical Industries Ltd.
• Kyowa Kirin Co., Ltd. (Kirin Company)
• Cadila Healthcare Ltd. (Zydus Cadila)
• Apotex, Inc.
• Toksöz Group

Unique Offerings from the Publisher

• Exhaustive coverage
• The highest number of market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free